167 results on '"Batus M"'
Search Results
2. PO-1451 Neutrophil-lymphocyte ratio dynamics associated with survival after SBRT for stage I-II lung cancer
3. CO154 Ramucirumab+Docetaxel Post Immune Checkpoint Inhibitors (ICIS) and Platinum-Based Chemotherapy (CHEMO) in Advanced or Metastatic Non-Small Cell Lung Cancer (ANSCLC): Learnings from the Treat-Lung Observational Study
4. Adrenal Stereotactic Body Radiation Therapy in the Management of Oligometastatic Lung Cancer: Patient Selection Matters
5. OA10.02 Psychosocial Distress in Patients with Driver-Mutant Lung Cancer
6. P76.30 The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in Patients with EGFR Mutated Advanced NSCLC
7. Impact of EGFR Mutational Status on Interfractional SBRT Lung Oligometastatic Tumor Response
8. Novel Autoantibodies Biomarkers Panel to Prognosticate the Clinical Outcomes in Advanced-stage NSCLC Patients Receiving Anti PD-1/PD-L1 Immunotherapy
9. P1.02 Chemotherapy with VMAT (Volumetric Modulated Arc Therapy) Radiation Therapy For Poor Risk Stage IIIA-C NSCLC Patients
10. P1.05 Clinical Factors Associated with Progression in Previously Treated Patients with Metastatic NSCLC on ANTI-PD-1 Therapy
11. OA03.01 Biomarkers of Autoimmune Toxicity in Metastatic SCLC Patients Receiving PD-1/PDL-1 Targeted Therapy
12. P1.21 RNA Pathway Enrichment in Serum Based Mass Spectroscopy Prognostic Analyses
13. OA01.02 Prognostic Value of Baseline Autoantibodies in Metastatic NSCLC Patients Receiving PD-/PDL-1 Targeted Immunotherapy
14. P2.04-69 Impact of Antibiotic Usage on Survival During Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer (NSCLC)
15. MA13.01 Associations Between Baseline Serum Biomarker Levels and Cachexia/Pre-Cachexia in Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients
16. P2.03-29 Circulating Levels of Ligands for Receptor Tyrosine Kinases May Contribute to an Immunosuppressive Tumor Microenvironment
17. PO-0776 Neutrophil-to-lymphocyte ratio dynamics predict for survival in lung cancer treated with SBRT
18. P2.01-12 Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients
19. P3.01-19 Sequencing of Ramucirumab+Docetaxel Post-Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients
20. P2.01-34 Prognostic Value of Neutrophil to Lymphocyte Ratio for Metastatic NSCLC Patients Treated with Immunotherapy and Ramucirumab Plus Docetaxel.
21. P3.01-05 Mature Progression-Free Survival in Stage IV Non-Small Cell Lung Cancer Patients Treated With Pemetrexed Maintenance Therapy
22. P2.01-61 Body Mass Index over Time is Associated with Overall Survival in Advanced NSCLC Patients Treated with Immunotherapy.
23. P2.12-16 Significant Tumor Regression and Toxicity with Nivolumab Plus Ipilimumab in Small Cell Lung Cancer Patients Following Radiation
24. PS02.13 Rapid Progression in 100% PDL-1 expressing NSCLC
25. PUB057 Neutrophil to Lymphocyte Ratio Predicts Survival in Advanced NSCLC Patients Treated with Second-Line PD-1 Immune Checkpoint Inhibitors
26. Decrease in Skeletal Muscle Index After Definitive Chemoradiation Therapy for Stage III Non–small Cell Lung Cancer is Associated With Decreased Overall Survival
27. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer
28. Improved Outcomes in Patients With Large, High-Grade Extremity Soft Tissue Sarcoma Treated With Mesna-Ifosfamide Doxorubicin (MAI) Neoadjuvant Chemotherapy and Interdigitated Radiation Therapy Followed by Resection and 3 More Cycles of MAI
29. Prognostic Factors for Survival After Recurrence of Stage III Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Therapy
30. Survival Benefit of Surgery Following Chemoradiation Therapy for Stage III NSCLC Is Dependent on Achieving Pathologic Nodal Clearance
31. Differences in Circulating Angiogenic Biomarkers as Prognosticator for Outcome in Bevacizumab-Treated Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Patients
32. Postinduction Inflammatory Status Predicts Complete Pathologic Response in Non-Small Cell Lung Cancer Patients Undergoing Induction Chemoradiation Therapy
33. Primary Tumor Volume, Bulky Adenopathy, and Number (But Not Location) of Involved Nodal Stations Predict Outcome in N2-N3 NSCLC Treated With Definitive Chemoradiation Therapy
34. Survival Outcomes in Patients With Nonsquamous Non-Small Cell Lung Cancer Treated With Pemetrexed- Versus Nonpemetrexed-Based Chemoradiation Therapy
35. Mesna-Ifosfamide Doxorubicin Chemoradiation Therapy (MAI-XRT) for Large, High-Grade Extremity Soft-Tissue Sarcoma: Reduced Toxicity and Encouraging Early Results
36. Survival Prediction in Ambulatory Stage III/ IV Non Small Cell Lung Cancer Patients Using the Palliative Performance Scale, Ecog and Lung Cancer Symptom Scale
37. PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy
38. Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).
39. Increased Bcl-2 expression is associated with Bax promoter hypermethylation in neuroendocrine carcinoma (NEC) of the lung.
40. Mcl-1 and bcl-2 expression in neuroendocrine carcinoma (NEC) and potential for new therapeutic target.
41. Postoperative survivin expression in stage III non-small cell lung cancer (NSCLC) patients treated with neoadjuvant chemoradiation.
42. Xanthine oxidoreductase and chemosensitivity in non-small cell lung cancer
43. N-cadherin, E-cadherin, ERCC1, and c-kit expression in small cell lung cancer (SCLC) and potential for new therapeutic targets
44. Frequency of insulin-like growth factor 1 (IGFR-1) expression and correlation with clinical and selected molecular parameters in advanced non-small cell lung cancer (NSCLC) patients (pts)
45. Assessing the impact of comorbidities on autologous hematopoietic cell transplant (AHCT) outcomes using the hematopoietic cell transplant-comorbidity index (HCT-CI) in lymphoma
46. N-cadherin, a potential novel therapeutic target in small cell lung cancer
47. The role of FDG-PET in low-grade non-Hodgkin lymphoma (NHL): Impact of histology
48. Effects of chromosomes 1, 3, 10 and 17 alterations on patient response to trastuzumab in metastatic breast cancer
49. Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients.
50. 1442 - Survival Prediction in Ambulatory Stage III/ IV Non Small Cell Lung Cancer Patients Using the Palliative Performance Scale, Ecog and Lung Cancer Symptom Scale
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.